JP2016527306A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527306A5
JP2016527306A5 JP2016532791A JP2016532791A JP2016527306A5 JP 2016527306 A5 JP2016527306 A5 JP 2016527306A5 JP 2016532791 A JP2016532791 A JP 2016532791A JP 2016532791 A JP2016532791 A JP 2016532791A JP 2016527306 A5 JP2016527306 A5 JP 2016527306A5
Authority
JP
Japan
Prior art keywords
acid
composition
skin
group
fabac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016532791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527306A (ja
Filing date
Publication date
Priority claimed from IL227890A external-priority patent/IL227890A0/en
Application filed filed Critical
Publication of JP2016527306A publication Critical patent/JP2016527306A/ja
Publication of JP2016527306A5 publication Critical patent/JP2016527306A5/ja
Pending legal-status Critical Current

Links

JP2016532791A 2013-08-08 2014-08-07 胆汁酸−脂肪酸抱合体を含む抗老化組成物 Pending JP2016527306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL227890A IL227890A0 (en) 2013-08-08 2013-08-08 Antiaging compounds containing bile acid and fatty acid conjugates
IL227890 2013-08-08
PCT/IL2014/050717 WO2015019358A1 (en) 2013-08-08 2014-08-07 Anti-aging compositions comprising bile acid-fatty acid conjugates

Publications (2)

Publication Number Publication Date
JP2016527306A JP2016527306A (ja) 2016-09-08
JP2016527306A5 true JP2016527306A5 (enExample) 2017-09-14

Family

ID=50022996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532791A Pending JP2016527306A (ja) 2013-08-08 2014-08-07 胆汁酸−脂肪酸抱合体を含む抗老化組成物

Country Status (9)

Country Link
US (1) US20160175223A1 (enExample)
EP (1) EP3030221A4 (enExample)
JP (1) JP2016527306A (enExample)
CN (1) CN105611910A (enExample)
AU (1) AU2014304078A1 (enExample)
CA (1) CA2920456A1 (enExample)
HK (1) HK1224198A1 (enExample)
IL (2) IL227890A0 (enExample)
WO (1) WO2015019358A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2920457A1 (en) * 2013-08-08 2015-02-12 Galderm Therapeutics Ltd. Anti-acne compositions comprising bile acid-fatty acid conjugates
WO2016199137A1 (en) 2015-06-10 2016-12-15 Galmed Research And Development Ltd. Low dose compositions of aramchol salts
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN109503693B (zh) * 2018-12-12 2021-04-06 合肥工业大学 一种利用胆酸为原料合成Aramchol的工艺
US20240315947A1 (en) * 2021-07-16 2024-09-26 Scai Therapeutics Co., Ltd. Cosmetic composition comprising molecular aggregates of bile acids or bile acid salts
EP4398890A4 (en) * 2021-09-09 2025-07-30 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The Univ Of Nevada Las Ve C. Difficile Spore Germination Inhibitors
WO2024012317A1 (zh) * 2022-07-14 2024-01-18 爱医谷(苏州)生物科技有限公司 一种用于抵抗衰老的组合物及其用途或方法
CN116236490A (zh) * 2023-02-14 2023-06-09 四川大学 脱氧胆酸的用途及药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115313A (en) * 1974-10-08 1978-09-19 Irving Lyon Bile acid emulsions
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US6019992A (en) * 1998-12-04 2000-02-01 Chesebrough-Pond's Usa Co. Cosmetic skin care compositions containing 4-chromanone
US8975246B2 (en) * 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
ES2296463B1 (es) * 2005-07-13 2009-02-16 Universidade De Santiago Compostela Nuevos amidoderivados de acidos billares funcionalizados en la posicion 3 del anillo a. procedimientos para su obtencion y aplicaciones.
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
KR20100138918A (ko) * 2008-03-11 2010-12-31 가부시키가이샤 시세이도 피부 미백 방법, 및, 피부 검버섯 형성 억제 및/또는 제거 인자의 스크리닝 방법
US8937194B2 (en) * 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
WO2010086864A1 (en) * 2009-02-02 2010-08-05 Galmed International Ltd. Methods and compositions for treating alzheimer's disease
CA2920457A1 (en) * 2013-08-08 2015-02-12 Galderm Therapeutics Ltd. Anti-acne compositions comprising bile acid-fatty acid conjugates
HUE045209T2 (hu) * 2013-12-04 2019-12-30 Galmed Res & Development Ltd Aramchol-sók

Similar Documents

Publication Publication Date Title
JP2016527306A5 (enExample)
JP2016527307A5 (enExample)
MX2021008981A (es) Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
HRP20201184T1 (hr) Spojevi alkilamida i njihove uporabe
MX2022006731A (es) Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
CO6640250A2 (es) Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua
AR067183A1 (es) Composiciones terapeuticas y metodos, usos y equipos
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
NO20092444L (no) Heteroarylamidderivater
JP2010511730A5 (enExample)
JP2016135810A5 (enExample)
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
JP2016540825A5 (enExample)
WO2008126076A3 (en) Low-dose mometasone formulations
JP2016510048A (ja) 毛髪処理の方法
EP3831839A3 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
TN2015000555A1 (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.
MA40149A1 (fr) Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial
MX2015003074A (es) Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas.
WO2014111570A3 (en) Cosmetic or dermatological composition comprising a merocyanine and an oily phase comprising at least one specific amide compound
MX363850B (es) Composicion cosmetica o dermatologica que comprende una merocianina, una fase aceitosa y un monoalcanol c1-c4.
RU2016148689A (ru) Комбинация тетрапептида и эфира глицерина для лечения андрогенной алопеции
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases